Lee CKM, et al. - Experts evaluated the nature of dermatitis after Programmed Death (PD)-1/ PD-Ligand (L)1 inhibitor exposure and oncologic outcomes associated with dermatitis. Results demonstrated the probability of lichenoid and spongiotic dermatitis associated with PD-1/PD-L1 inhibitors to be a sign of robust immune response and improved oncologic outcomes. Lichenoid dermatitis (50%) and spongiotic dermatitis (40%) were the most common histologic patterns. For cases, overall tumour response rate was 65.0% and 17.0% for controls, odds ratio: 7.3.